Arrowhead and Sarepta link for rare genetic disease treatments
Arrowhead Pharmaceuticals has entered a worldwide licensing and partnership agreement with Sarepta Therapeutics to develop treatments for rare genetic diseases. Arrowhead will receive an $825m payment: $500m in cash and a $325m equity investment at a 35% premium.
Gil Blum, an analyst from Needham, reiterated the Buy rating on Sarepta Therapeutics (SRPT – Research Report). The associated price target was ...
Intellia Therapeutics received the FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for nexiguran ziclumeran ...
Sarepta Therapeutics is paying Arrowhead Pharmaceuticals $500 million in cash, plus a $325 million equity investment, for ...
Sarepta Therapeutics (SRPT – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Tazeen Ahmad from Bank of America Securities reiterated a ...
Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) shares are trading higher Tuesday after the company announced a global ...
Roche announced it will acquire Poseida Therapeutics in a deal worth up to $1.5 Billion. The deal allows the Swiss company ...
Don't Miss our Black Friday Offers: An announcement from Sarepta Therapeutics ( (SRPT)) is now available. Sarepta Therapeutics is undergoing a leadership change as Ryan Brown steps down, with ...
Analysts have set 12-month price targets for Sarepta Therapeutics, revealing an average target of $168.79, a high estimate of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback